Author:
Lu Yalan,Huang Rong,Ying Jianming,Li Xingchen,Jiao Tao,Guo Lei,Zhou Haitao,Wang Han,Tuersuntuoheti Amannisa,Liu Jianmei,Chen Qichen,Wang Yanhong,Su Luying,Guo Changyuan,Xu Fu,Wang Ziyi,Lu Yan,Li Kai,Liang Junbo,Huang Zhen,Chen Xiao,Yao Jinjie,Hu Hanjie,Cheng Xiaowen,Wan Yufeng,Chen Xinyan,Zhang Ning,Miao Shiying,Cai Jianqiang,Wang Linfang,Liu Changzheng,Song Wei,Zhao Hong
Abstract
AbstractProlonged activation of nuclear factor (NF)-кB signaling significantly contributes to the development of colorectal cancer (CRC). New therapeutic opportunities are emerging from targeting this distorted cell signaling transduction. Here, we discovered the critical role of RING finger 138 (RNF138) in CRC tumorigenesis through regulating the NF-кB signaling, which is independent of its Ubiquitin-E3 ligase activity involved in DNA damage response. RNF138−/− mice were hyper-susceptible to the switch from colitis to aggressive malignancy, which coincided with sustained aberrant NF-кB signaling in the colonic cells. Furthermore, RNF138 suppresses the activation of NF-кB signaling pathway through preventing the translocation of NIK and IKK-Beta Binding Protein (NIBP) to the cytoplasm, which requires the ubiquitin interaction motif (UIM) domain. More importantly, we uncovered a significant correlation between poor prognosis and the downregulation of RNF138 associated with reinforced NF-кB signaling in clinical settings, raising the possibility of RNF138 dysregulation as an indicator for the therapeutic intervention targeting NF-кB signaling. Using the xenograft models built upon either RNF138-dificient CRC cells or the cells derived from the RNF138-dysregulated CRC patients, we demonstrated that the inhibition of NF-кB signaling effectively hampered tumor growth. Overall, our work defined the pathogenic role of aberrant NF-кB signaling due to RNF138 downregulation in the cascade events from the colitis switch to colonic neoplastic transformation and progression, and also highlights the possibility of targeting the NF-кB signaling in treating specific subtypes of CRC indicated by RNF138-ablation.
Publisher
Springer Science and Business Media LLC